Susoctocog alfa

Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.[2][3]

Susoctocog alfa
Clinical data
Trade namesObizur
Other namesAntihemophilic factor (recombinant)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • US: C (Risk not ruled out) [1]
    Drug classAntihemophilic factor
    ATC code
    Legal status
    Legal status
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    DrugBank
    UNII

    Susoctocog alfa was approved for medical use in the United States in October 2014,[4][5] and for medical use in the European Union in November 2015.[2]

    Factor VIII is one of the proteins needed for normal clotting of the blood.[2]

    References
    1. "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Retrieved 6 March 2020.
    2. "Obizur EPAR". European Medicines Agency. 6 March 2020. Retrieved 6 March 2020.
    3. "Obizur (antihemophilic factor- recombinant, porcine sequence kit". DailyMed. 2 January 2020. Retrieved 6 March 2020.
    4. "Obizur". U.S. Food and Drug Administration (FDA). 13 March 2018. Archived from the original on 23 April 2019. Retrieved 6 March 2020.
    5. "Obizur". U.S. Food and Drug Administration (FDA). 27 September 2019. STN: BL 125512. Retrieved 6 March 2020.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.